Mulder P, Compagnon P, Devaux B, Richard V, Henry J P, Elfertak L, Wimart M C, Thibout E, Comoy E, Macé B, Thuillez C
Department of Pharmacology, VACOMED, IFRMP no 23, Rouen University Medical School, France.
Fundam Clin Pharmacol. 1997;11(3):221-30. doi: 10.1111/j.1472-8206.1997.tb00189.x.
The increased sympathetic drive in chronic heart failure (CHF) might provoke vascular adrenoceptor desensitization, which, together with endothelial dysfunction, could contribute to the altered vasomotor tone seen in CHF. We investigated 1) whether CHF alters the responses mediated by alpha and beta adrenoceptors in small and large peripheral arteries, and 2) the effect of angiotensin-converting enzyme (ACE) inhibition. Rats with CHF (coronary artery ligation) were treated with placebo or the ACE inhibitor lisinopril (10 mg/kg/d) starting 7 days after ligation. Responses to phenylephrine (alpha 1 agonist), salbutamol (beta 2 agonist) as well as acetylcholine (endothelium-dependent), were assessed after 3 months in isolated and pressurized segments of the abdominal aorta, the femoral and the mesenteric arteries. In animals with hemodynamic signs of CHF, neither the vasoconstrictor responses to phenylephrine nor the vasodilator response to salbutamol were affected. In contrast, the dilator response to acetylcholine of both small arteries, but not that of the aorta, was impaired. Furthermore, CHF did not modify vessel structure. While lisinopril did not modify the responses to adrenergic agonists, it normalized the response to acetylcholine. Furthermore, ACE inhibition reduced vascular media cross sectional area and collagen density. Thus, the unchanged arterial responsiveness to adrenoceptor agonists does not indicate any vascular adrenoceptor desensitization, while endothelial dependent vasodilation of small arteries is impaired in CHF. ACE inhibition does not modify the response to adrenergic stimuli, prevents endothelial dysfunction and induces both cardiac and vascular remodeling, which probably contribute to the effect ACE inhibitors have on exercise tolerance and survival.
慢性心力衰竭(CHF)中交感神经驱动增加可能会引发血管肾上腺素能受体脱敏,这与内皮功能障碍一起,可能导致CHF中出现的血管运动张力改变。我们研究了:1)CHF是否会改变外周小动脉和大动脉中α和β肾上腺素能受体介导的反应;2)血管紧张素转换酶(ACE)抑制的作用。CHF大鼠(冠状动脉结扎)在结扎后7天开始接受安慰剂或ACE抑制剂赖诺普利(10mg/kg/d)治疗。3个月后,在离体并加压的腹主动脉、股动脉和肠系膜动脉节段中评估对去氧肾上腺素(α1激动剂)、沙丁胺醇(β2激动剂)以及乙酰胆碱(内皮依赖性)的反应。在有CHF血流动力学体征的动物中,对去氧肾上腺素的血管收缩反应和对沙丁胺醇的血管舒张反应均未受影响。相比之下,小动脉对乙酰胆碱的舒张反应受损,而主动脉的未受损。此外,CHF并未改变血管结构。虽然赖诺普利未改变对肾上腺素能激动剂的反应,但它使对乙酰胆碱的反应恢复正常。此外,ACE抑制降低了血管中膜横截面积和胶原密度。因此,动脉对肾上腺素能受体激动剂的反应性未改变并不表明存在任何血管肾上腺素能受体脱敏,而CHF中小动脉的内皮依赖性血管舒张受损。ACE抑制并未改变对肾上腺素能刺激的反应,可预防内皮功能障碍并诱导心脏和血管重塑,这可能有助于解释ACE抑制剂对运动耐量和生存率的影响。